AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Jul 17, 2017
35334_dirs_2017-07-17_aec73c51-945b-4cad-9594-ba5e870a5128.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-07-15
Reporting Person: Equels Thomas K. (Director, CEO / President)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-07-15 | Options to buy Common Stock | $0.48 | A | 18124 | Acquired | 2027-07-15 | Common Stock (18124) | Direct |
Footnotes
F1: This option is being issued in exchange for a voluntary 20% deduction in salary.